Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

Published:2014-06 Issue:3 Volume:36 Page:326-334
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Lankheet Nienke A. G.,Knapen Lotte M.,Schellens Jan H. M.,Beijnen Jos H.,Steeghs Neeltje,Huitema Alwin D. R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference39 articles.

1. Tyrosine kinases as targets for cancer therapy.;Krause;N Engl J Med,2005

2. . Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.;Burris;J Clin Oncol,2005

3. Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs.;Calvo;Clin Lung Cancer,2004

4. . Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.;Delbaldo;Clin Cancer Res,2006

5. . Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.;Hidalgo;J Clin Oncol,2001

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes;ESMO Open;2024-06

2. Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists;Internal Medicine Journal;2024-05-20

3. Association between plasma imatinib levels and response to treatment of chronic myeloid leukemia in patients from Manaus, Brazil;Journal of Oncology Pharmacy Practice;2024-05-06

4. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients;Journal of Chromatography B;2024-04

5. On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models;Journal of Pharmacokinetics and Pharmacodynamics;2024-03-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3